218 related articles for article (PubMed ID: 36134475)
1. Identification of Dihydroorotate Dehydrogenase Inhibitors Using the Cell Painting Assay.
Schölermann B; Bonowski J; Grigalunas M; Burhop A; Xie Y; Hoock JGF; Liu J; Dow M; Nelson A; Nowak C; Pahl A; Sievers S; Ziegler S
Chembiochem; 2022 Nov; 23(22):e202200475. PubMed ID: 36134475
[TBL] [Abstract][Full Text] [Related]
2. A Patent Review of Human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors as Anticancer Agents and their Other Therapeutic Applications (1999-2022).
Gehlot P; Vyas VK
Recent Pat Anticancer Drug Discov; 2024; 19(3):280-297. PubMed ID: 37070439
[TBL] [Abstract][Full Text] [Related]
3. Recent developments in the medicinal chemistry and therapeutic potential of dihydroorotate dehydrogenase (DHODH) inhibitors.
Vyas VK; Ghate M
Mini Rev Med Chem; 2011 Oct; 11(12):1039-55. PubMed ID: 21861807
[TBL] [Abstract][Full Text] [Related]
4. Dihydroorotate dehydrogenase inhibitors in anti-infective drug research.
Boschi D; Pippione AC; Sainas S; Lolli ML
Eur J Med Chem; 2019 Dec; 183():111681. PubMed ID: 31557612
[TBL] [Abstract][Full Text] [Related]
5. Development of a biomarker to monitor target engagement after treatment with dihydroorotate dehydrogenase inhibitors.
Pontikos MA; Leija C; Zhao Z; Wang X; Kilgore J; Tornesi B; Adenmatten N; Phillips MA; Williams NS
Biochem Pharmacol; 2022 Oct; 204():115237. PubMed ID: 36055381
[TBL] [Abstract][Full Text] [Related]
6. SAR studies toward discovery of emvododstat (PTC299), a potent dihydroorotate dehydrogenase (DHODH) inhibitor.
Baiazitov RY; Qi H; Arasu T; Lennox W; Cao L; Weetall M; Furia B; Zhuo J; Choi S; Kim MJ; Sheedy J; Davis T; Moon YC
Eur J Med Chem; 2022 Dec; 244():114826. PubMed ID: 36242990
[TBL] [Abstract][Full Text] [Related]
7. Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer.
Madak JT; Bankhead A; Cuthbertson CR; Showalter HD; Neamati N
Pharmacol Ther; 2019 Mar; 195():111-131. PubMed ID: 30347213
[TBL] [Abstract][Full Text] [Related]
8. Recent advances on patents of
Gehlot P; Vyas VK
Expert Opin Ther Pat; 2023; 33(9):579-596. PubMed ID: 37942637
[TBL] [Abstract][Full Text] [Related]
9. A comprehensive drug repurposing study for COVID19 treatment: novel putative dihydroorotate dehydrogenase inhibitors show association to serotonin-dopamine receptors.
Berber B; Doluca O
Brief Bioinform; 2021 Mar; 22(2):1023-1037. PubMed ID: 33406218
[TBL] [Abstract][Full Text] [Related]
10. The Warburg effect modulates DHODH role in ferroptosis: a review.
Amos A; Amos A; Wu L; Xia H
Cell Commun Signal; 2023 May; 21(1):100. PubMed ID: 37147673
[TBL] [Abstract][Full Text] [Related]
11. A Novel mechanism of herbicide action through disruption of pyrimidine biosynthesis.
Kang IH; Emptage RP; Kim SI; Gutteridge S
Proc Natl Acad Sci U S A; 2023 Nov; 120(48):e2313197120. PubMed ID: 37988466
[TBL] [Abstract][Full Text] [Related]
12. ENT1 blockade by CNX-774 overcomes resistance to DHODH inhibition in pancreatic cancer.
Mullen NJ; Thakur R; Shukla SK; Chaika NV; Kollala SS; Wang D; He C; Fujii Y; Sharma S; Mulder SE; Sykes DB; Singh PK
Cancer Lett; 2023 Jan; 552():215981. PubMed ID: 36341997
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of pyrimidine biosynthesis targets protein translation in acute myeloid leukemia.
So J; Lewis AC; Smith LK; Stanley K; Franich R; Yoannidis D; Pijpers L; Dominguez P; Hogg SJ; Vervoort SJ; Brown FC; Johnstone RW; McDonald G; Ulanet DB; Murtie J; Gruber E; Kats LM
EMBO Mol Med; 2022 Jul; 14(7):e15203. PubMed ID: 35514210
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the de novo pyrimidine biosynthesis pathway limits ribosomal RNA transcription causing nucleolar stress in glioblastoma cells.
Lafita-Navarro MC; Venkateswaran N; Kilgore JA; Kanji S; Han J; Barnes S; Williams NS; Buszczak M; Burma S; Conacci-Sorrell M
PLoS Genet; 2020 Nov; 16(11):e1009117. PubMed ID: 33201894
[TBL] [Abstract][Full Text] [Related]
15. Biochemical characterization of Mycobacterium tuberculosis dihydroorotate dehydrogenase and identification of a selective inhibitor.
Alberti M; Sainas S; Ronchi E; Lolli ML; Boschi D; Rizzi M; Ferraris DM; Miggiano R
FEBS Lett; 2023 Aug; 597(16):2119-2132. PubMed ID: 37278160
[TBL] [Abstract][Full Text] [Related]
16. Functional expression of human dihydroorotate dehydrogenase (DHODH) in pyr4 mutants of ustilago maydis allows target validation of DHODH inhibitors in vivo.
Zameitat E; Freymark G; Dietz CD; Löffler M; Bölker M
Appl Environ Microbiol; 2007 May; 73(10):3371-9. PubMed ID: 17369345
[TBL] [Abstract][Full Text] [Related]
17. The pathway to pyrimidines: The essential focus on dihydroorotate dehydrogenase, the mitochondrial enzyme coupled to the respiratory chain.
Löffler M; Carrey EA; Knecht W
Nucleosides Nucleotides Nucleic Acids; 2020; 39(10-12):1281-1305. PubMed ID: 32043431
[TBL] [Abstract][Full Text] [Related]
18. Dihydroorotate dehydrogenase (DHODH) inhibitors affect ATP depletion, endogenous ROS and mediate S-phase arrest in breast cancer cells.
Mohamad Fairus AK; Choudhary B; Hosahalli S; Kavitha N; Shatrah O
Biochimie; 2017 Apr; 135():154-163. PubMed ID: 28196676
[TBL] [Abstract][Full Text] [Related]
19. Dihydroorotat-ubiquinone oxidoreductase links mitochondria in the biosynthesis of pyrimidine nucleotides.
Löffler M; Jöckel J; Schuster G; Becker C
Mol Cell Biochem; 1997 Sep; 174(1-2):125-9. PubMed ID: 9309676
[TBL] [Abstract][Full Text] [Related]
20. DHODH: a promising target in the treatment of T-cell acute lymphoblastic leukemia.
Sexauer AN; Alexe G; Gustafsson K; Zanetakos E; Milosevic J; Ayres M; Gandhi V; Pikman Y; Stegmaier K; Sykes DB
Blood Adv; 2023 Nov; 7(21):6685-6701. PubMed ID: 37648673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]